Unlocking the Potential of Immunotherapy
Ability to Potentiate PD-1 Inhibitors
Prolonged Progression Free Survival in PD-1 Resistant Patients
Durable Responses in PD-1 Resistant Patients
Our new anti-cancer agents have the potential to change the standards of care for patients across a broad range of cancers
We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. Utilizing our proprietary phosphoramidate technology we are developing more effective and safer anti-cancer medicines.
NuCana is led by a highly experienced management team with extensive drug development & commercialization expertise.
Mission Statement
“To significantly improve the survival outcomes for patients and pioneer a new era in oncology”.
Hugh S. Griffith - Founder & CEO
Latest News
Contact NuCana
Global Headquarters
3 Lochside Way, Edinburgh, EH12 9DT, UK
US Office
275 Grove Street, Newton, MA 02466